FIG 5.
PSV binding and infection require terminal α2,3-linked SA. (A) Binding of AF-594-labeled PSV (MOI, 1,000 PFU/cell) was examined by confocal microscopy after pretreating LLC-PK cells with MAL or SNL. (B) The effect of pretreament of MAL or SNL to each corresponding cell on the binding of [35S]methionine-cysteine-labeled PSV, EV70, FCV, and CVB3 strains (50,000 cpm) was examined by liquid scintillation counting and expressed as a percentage of the value for the mock-treated, virus-infected control. (C) The effect of MAL or SNL pretreatment of permissive cells on the infectivity of PSV (MOI, 1 PFU/cell) was assessed by immunofluorescence using monoclonal antibody specific for PSV capsid protein at 15 h postinfection. (D) The levels of PSV, EV70, FCV, or CVB3 antigen-positive cells expressed as percentages of the mock-treated, virus-infected cells were quantified from three independent fields of view. All experiments were performed three independent times. Panels A and C show representative sets of results. The scale bars correspond to 20 μm. Error bars indicate SD from triplicate experiments. *, P < 0.05; **, P < 0.005.